.ANALYSIS EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the add-on of perioperative durvalumab to basic procedure for muscle-invasive sac cancer cells boosted event-free and also on the whole survival, noting a new treatment choice for this ailment.